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PEffects of Ile164 Polymorphism of Beta2-Adrenergic
Receptor Gene on Coronary Artery Disease
Federico Piscione, MD, Guido Iaccarino, MD, Gennaro Galasso, MD, Ersilia Cipolletta, MD,
Maria Assunta Rao, MD, Gregorio Brevetti, MD, Raffaele Piccolo, MD, Bruno Trimarco, MD,
Massimo Chiariello, MD
Naples, Italy
Objectives This study investigated the relationship between beta2-adrenergic receptor (B2AR) Ile164 polymorphism and
coronary artery disease (CAD).
Background B2ARs are crucial to the regulation of vascular tone, and neoangiogenesis is impaired in the presence of isoleu-
cine at position 164 (Ile164) B2AR gene polymorphism. No data deal with the role of the variants at position
164 of the B2AR gene in the setting of CAD.
Methods The study population consisted of 330 patients undergoing percutaneous coronary intervention (PCI).
Results The Ile164 polymorphism frequency was higher in CAD (12.1% vs. 3%, p  0.008) with respect to the control
population. We divided our population into 2 groups: group 1 (290 patients, threonine/threonine genotype at
position 164 [164Thr/Thr]) and group 2 (40 patients, threonine/isoleucine genotype at position 164 [164Thr/
Ile]). Patients of group 2 presented an earlier onset of CAD (56.7  7.8 vs. 59.5  10, p  0.04) and a higher
incidence of multivessel disease (25.4% vs. 41%, p  0.044). At follow-up, group 2 showed a higher incidence
of new acute myocardial infarction (17.5% vs. 4.5%, p  0.001), new PCI (37.5% vs. 13.1%, p  0.0001), and
cardiac death (10% vs. 3.1%, p  0.036). Cox regression analysis identified Ile164 as an independent predictor
of cardiac death (odds ratio [OR]: 3.731, 95% confidence interval [CI]: 1.004 to 13.867, p  0.049) and an over-
all major adverse cardiac event (OR: 4.100, 95% CI: 1.945 to 8.640, p  0.0001). A replication study was done
on a population of 150 patients with peripheral artery disease. The presence of the Ile164 allele was associated
with a higher incidence of acute myocardial infarction (54.5% vs. 25.2%, p  0.035) or combined events (acute
myocardial infarction, PCI, or coronary artery bypass graft) (63.6% vs. 30.9%, p  0.027).
Conclusions Our study suggests that the B2AR Ile164 mutant is associated with a more aggressive CAD and adversely af-
fects prognosis in patients undergoing PCI. (J Am Coll Cardiol 2008;52:1381–8) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.034a
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ohe sequence of human beta2-adrenergic receptor (B2AR)
s highly polymorphic, and there are 3 major coding
equence polymorphisms: arginine at position 16 replaced
y glycine (Arg16Gly), glutamine at position 27 replaced by
lutamic acid (Gln27Glu), and threonine at position 164
eplaced by isoleucine (ThrIle164) (1). The functional
elevance of these variants has been extensively evaluated in
ells (2–4) and in transgenic mice (5) and is mostly related
o cardiac function (2,3). In particular, the isoleucine
Ile164) substitution of the threonine in position 164 causes
hat receptor to have decreased basal and agonist-stimulated
denylyl cyclase activities and decreased affinity for B2AR
rom the Department of Clinical Medicine, Cardiovascular and Immunology
ciences, Federico II University School of Medicine, Naples, Italy. Drs. Piscione and
accarino contributed equally to this work.(
Manuscript received May 28, 2008; revised manuscript received July 7, 2008,
ccepted July 10, 2008.gonists (6). Taking into consideration the pathophysiolog-
cal consequences of polymorphic B2AR, it is important to
ote that B2ARs are highly expressed throughout the
ardiovascular system, in which they mediate increased
yocardial inotropism and chronotropism (7,8) and regu-
ate coronary vasodilation (9). Recently, we have demon-
See page 1389
trated that the endothelial B2AR contributes to vasorelax-
tion and to post-ischemic angiogenesis (10). Interestingly,
he Ile164 variant of the B2AR appears to lose the ability to
odulate such responses. Similarly, vasodilation in humans
arrying the Ile164 variant of the B2AR gene is impaired
6). To date, no data deal with the role of the Ile164 variant
f the B2AR gene in the setting of coronary artery disease
CAD). It is well known that CAD is not a consequence of
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environmental factor, but rather
it is a complex, multifactorial dis-
ease. Moreover, the field of
B2AR polymorphism research,
particularly with regard to clini-
cal associations, is characterized
by rather controversial data being
reported. Overall, the available
clinical association data have
proved to be rather disappointing
as most originally proposed rela-
tionships have not been consis-
tently replicated in later studies
(11,12). This study was designed
to investigate the relationship
between B2AR Ile164 polymor-
phism and CAD.
Methods
In Vivo Study
Patients. The study population
consisted of 330 consecutive pa-
tients (mean age 60  11 years,
84% male) undergoing elective or
urgent percutaneous coronary in-
tervention (PCI) for CAD doc-
umented by a positive stress test
or by Tl single photon emission
computed tomography or acute
coronary syndrome. At the time
of PCI, peripheral blood was
drawn to determine the B2AR
enotype. To identify normal distribution of the B2AR
enotype, we enrolled a control population of 100 gender-
nd age-matched healthy unrelated individuals (58  10
ears, 80% male), recruited from blood donors of our blood
ank. Controls were free from heart disease, medication use,
nd cardiovascular risk factors, except for smoking habits. A
eplication analysis was performed on an independent pop-
lation of the PACE (Prevention by Low Dose Aspirin of
ardiovascular Disease in the Elderly) study, which was
onducted in patients affected by peripheral artery disease
PAD) (13). To determine B2AR genotype in these pa-
ients, blood samples from 150 patients (men 60%, mean
ge 67  8 years) were drawn during a scheduled follow-up
isit. A written informed consent was obtained from all
atients according to the Ethics Committee of the Federico
I University of Naples School of Medicine.
CI procedure. PCI was performed according to the
merican Heart Association/American College of Cardiol-
gy guidelines (14). Antegrade perfusion was graded by
hrombolysis In Myocardial Infarction (TIMI) criteria
15). Angiographic lesion morphology was classified accord-
Abbreviations
and Acronyms
Ad  adenoviral
AMI  acute myocardial
infarction
B2AR  beta2-adrenergic
receptor
CAD  coronary artery
disease
DNA  deoxyribonucleic
acid
ERK  extracellular signal-
related kinase
IBS  integrated
backscatter
IMT  intima-media
thickness
ISO  isoproterenol
MACE  major adverse
cardiac event
PAD  peripheral artery
disease
PCI  percutaneous
coronary intervention
PCR  polymerase chain
reaction
Rb  retinoblastoma
protein
TIMI  Thrombolysis In
Myocardial Infarction
VSMC  vascular smooth
muscle cell
WT  wild typeng to American Heart Association/American College of sardiology classification (16). Stenoses 50% were consid-
red significant. All patients received bare-metal stents to
ptimize acute and long-term procedural results. Glycopro-
ein IIb/IIIa inhibitors were used in 30% of patients. After
he procedures, all patients were on dual antiplatelet therapy
ith aspirin and clopidogrel for 30 days. Long-term med-
cal treatment was left to the discretion of the attending
ardiologists.
ollow-up. In the evaluation of long-term clinical out-
ome, major adverse cardiac events (MACE) were consid-
red as end points, including cardiac death, acute myocar-
ial infarction (AMI), new PCI, bypass cardiac surgery, and
evelopment of congestive heart failure. The follow-up was
ased on a direct systematic review of all patients’ clinical
les for a mean study period of 36  4 months, contacting
elatives or a patient’s physician when necessary. Follow-up
as completed in all patients and data stored in a comput-
rized database.
arotid ultrasound analysis. Twelve patients (6 with
2AR Ile164 and 6 with B2AR threonine in position 164
Thr164]) were selected to be within 1 SD of the average for
ge and risk factors for atherosclerosis. A carotid ultrasound
xamination was performed using a 7.5-MHz, linear-array
ransducer (SONOS-5500, Philips Healthcare, Andover,
assachusetts) as previously described (17). The operator
erformed all of the carotid scans without any information
n the genotype. Intima-media thickness (IMT) was de-
ned as the distance from the leading edge of the lumen-
ntima interface to the leading edge of the media-adventitia
nterface. Atherosclerotic plaque was defined as a lesion
ith focal IMT of 1.5 mm or more with a localized
rotrusion of the vessel wall into the lumen. Integrated
ackscatter (IBS) values of all carotid atherosclerotic plaques
ere measured as described previously (18), expressing the
elative IBS value of the intima-media complex as the
ifference in IBS values between the intima-media and
dventitia.
2AR genotyping. Using a commercially available kit
Midiprep DNA, Qiagen, Valencia, California), genomic
eoxyribonucleic acid (DNA) was isolated from 2 ml of
he peripheral blood samples. The Ile164 B2AR gene
olymorphism was studied using combined polymerase
hain reaction (PCR) and restriction fragment length
olymorphism technique on PCR amplified products
sing PCR conditions and primers on a Thermocycler
MJ Research, St. Bruno, Canada) and DNA polymerase
TAQ, Qiagen) (19).
n Vitro Study
denoviral mediated gene transfer of the B2AR gene in
ascular smooth muscle cells. We used adenoviral vectors
ncoding for the human B2AR wild-type (WT) gene and
he B2AR-Ile164 mutant gene as previously reported
10,20,21). Cells were infected at a multiplicity of infection
f 100 plaque-forming units per cell, in the presence of
erum for 3 h at 37°C.
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October 21, 2008:1381–8 Ile164 Polymorphism and CAD3H]-thymidine incorporation. Vascular smooth muscle
ells (VSMCs) were starved for 24 h and then incubated in
ulbecco modified Eagle medium with [3H] thymidine and
eta-AR agonist isoproterenol (ISO) (107 mol/l). After
4 h, thymidine incorporation was evaluated as described
lsewhere (22).
ell culture and proliferation. Arterial VSMCs were
btained from rat aorta by enzymatic digestion, as described
lsewhere (23). Cells were grown in plastic dishes in
edium 199 supplemented with 10% fetal bovine serum
nd 1% penicillin-streptomycin and studied between pas-
ages 4 and 10. The VSMCs were seeded at a density of
0,000 per well in 6-well plates, serum starved overnight,
nd then stimulated with ISO. Cell numbers were studied at
, 12, and 24 h after stimulation with ISO 107 mol/l. At
ny of the time points, medium was removed, detached
rom plate by 3 min trypsin incubation, and counted on a
emocytometer.
2AR density and membrane adenylyl cyclase activity
ssays. Crude cell membranes were prepared as previously
escribed. The B2AR density was determined by radioli-
and binding with the nonselective B2AR ligand 125I-
abeled iodocyanopindolol using standard methods (24).
estern blot. The VSMCs were stimulated with ISO for
min for extracellular signal-regulated kinase (ERK) or up
o 9 h for phosphorylated retinoblastoma protein (Rb) and
hen dissolved in radioimmunoprecipitation assay–sodium
odecylsulfate buffer. Protein were electrophoresed by so-
ium dodecylsulfate/polyacrylamide gel electrophoresis and
ransferred to nitrocellulose; Rb, phosphorylated ERK1/2,
otal ERK (Cell Signaling Technology, Danvers, Massa-
husetts), and actin (Santa Cruz Biotechnology, Santa
ruz, California) were visualized by specific antibodies,
ntirabbit horseradish peroxidase–conjugated secondary an-
ibody (Santa Cruz) and standard chemiluminescence
Pierce Biotechnology, Rockford, Illinois) on autoradio-
raphic films. Autoradiographs were then digitalized and
ensitometry quantification performed using dedicated soft-
are (ImageQuant, Molecular Dynamics, Sunnyvale, Cali-
ornia). Data are presented as arbitrary densitometry units
fter normalization for the total corresponding protein or
ctin as internal control.
tatistical analysis. Continuous variables are presented as
ean  SD and categorical variables as absolute number
nd percentage value. Differences between groups were
ssessed using univariate analysis of variance for continuous
ariables, with a Bonferroni post-hoc test for evaluation of
ultiple comparisons. Categorical variables were analyzed
y chi-square test, and odds ratio (OR) with 95% confi-
ence intervals (CIs) or by the Fisher exact test when the
xpected values in any of the cells of the test, given the
requencies and the overall sample size, was below 10;
value 0.05 was considered significant. Difference in
vent-free survival between groups were evaluated by the
aplan-Meier method, comparisons were made using log-ank test. A Cox regression analysis was conducted for the
N
i64 position B2AR polymorphism considering age, cardio-
ascular risk factors, medication use, left ventricular ejection
raction, angiographic characteristics, and interaction of the
64th position B2AR polymorphism in both the study
opulations. The computer program used was SPSS 12.1
SPSS Inc., Chicago, Illinois).
esults
hrIle164 frequencies. In line with previously reported
ata, we could not find homozygous Ile164 individuals in
tudies and control groups. Of note, the frequency of the
le164 allele was significantly higher in the CAD population
s compared with the healthy population (12.1% vs. 3%,
espectively, p  0.008). We, therefore, focused on the
ffects of Ile164 polymorphism on clinical, angiographic,
nd prognostic characteristics of CAD. The study popula-
ion was divided into 2 groups: group 1 (290 patients,
hreonine/threonine genotype at position 164 [164Thr/
hr]; 86% male, mean age 60  10 years) and group 2 (40
atients, threonine/isoleucine genotype at position 164
164Thr/Ile]; 83% male, mean age 60  8.57 years).
opulation clinical characteristics. There were no differ-
nces between groups with regard to clinical features (Table 1).
ccordingly, the preprocedural left ventricular ejection frac-
ion was similar between groups (46.3  8% vs. 49.4 
0%, p NS). However, when we considered the age when
AD was first diagnosed, patients of group 2 were signif-
cantly younger, thus suggesting an earlier onset of CAD
56.7  8 years vs. 59.6  10 years, p  0.04) in patients
arboring the Ile164 polymorphism.
opulation angiographic characteristics. Group 2 pre-
ented more severe angiographic CAD as indicated by the
igher incidence of multivessel disease, and by a larger
ccurrence of type B2/C lesions (Table 2). Accordingly, the
linical Characteristics of B2AR Ile164 Patients
Table 1 Clinical Characteristics of B2AR Ile164 Patients
Variable
Group 1
(n  290)
Group 2
(n  40) p Value
Age at CAD diagnosis (yrs),
mean  SD
59.5 10 56.7 7.8 0.04
Hypertension, % 54.5 62.5 NS
Diabetes, % 24.5 32.5 NS
Dyslipidemia, % 53.1 55 NS
Family history of CAD, % 40.3 47.5 NS
Obesity, % 7.2 5 NS
Smoker, % 56.2 57.5 NS
Previous history of CAD, % 47.6 48.7 NS
Previous MI, % 37.5 45 NS
Previous PCI, % 13.3 7.5 NS
Previous CABG, % 5.7 1 NS
ACS NSTEMI at PCI time, % 40 49 NS
MI at PCI time, % 17 21 NS
EF prior to PCI (%), mean  SD 46.35 8 49.43 10 NS
CS  acute coronary syndrome; B2AR  beta2-adrenergic receptor; CABG  coronary artery
ypass graft; CAD  coronary artery disease; EF  ejection fraction; MI  myocardial infarction;
STEMI  non–ST-segment elevated myocardial infarction; PCI  percutaneous coronary
ntervention.
n
g
M
r
f
s
9
g
N
3
p
L
e
i
(
f
i
a
(
3
f
(
(
e
(
o
0
s
t
i
e
B
o
e
o
p
t
a
i
t
c
p
f
w
c
2
c
I
r
b
c
C
w
t
a
d
I
I
t
g
p
d
g
I
I
t
a
I
p
c
i
a
I
t
y
c
l
s
p
A
C
c
1384 Piscione et al. JACC Vol. 52, No. 17, 2008
Ile164 Polymorphism and CAD October 21, 2008:1381–8umber of vessels treated by PCI was significantly higher in
roup 2.
edication use. There were no differences between groups
egarding medication use at the time of PCI and during
ollow-up. In particular, at follow-up time both groups were
imilarly treated, using double antiplatelets therapy (99% vs.
8% group 2, p  NS), calcium antagonist (19% vs. 18%
roup 2, p NS), beta-blockers (45% vs. 47% group 2, p
S), angiotensin-converting enzyme inhibitors (36% vs.
4% group 2, p  NS), and statins (42% vs. 40% group 2,
 NS).
ong-term follow-up. There were no significant differ-
nces between groups regarding MACE incidence during
n-hospital stay. At long-term follow-up, the rate of PCI
37.5% vs. 13.1%, p  0.0001), and development of heart
ailure (12.5% vs. 2.1%, p 0.001) were significantly higher
n group 2. Furthermore, patients harboring the Ile164
llele showed a significantly increased rate of new AMI
17.5% vs. 4.5%, p  0.001) and cardiac death (10% vs.
.1%, p  0.036). Accordingly, the Kaplan-Meier analysis
or event-free survival in patients harboring the Ile164 allele
Fig. 1) showed worse long-term outcome for these patients
p  0.0001). Cox regression analysis identified the pres-
nce of Ile164 as an independent predictor for cardiac death
OR: 3.731, 95% CI: 1.004 to 13.867, p  0.049) and
verall MACE (OR: 4.100, 95% CI: 1.945 to 8.640, p 
.0001). There were no interactions noted for this relation-
hip when considering age, risk factors for CAD, medica-
ion use at follow-up time, previous myocardial revascular-
zation, number of treated lesions, and basal left ventricular
jection fraction.
2AR Ile164 frequencies in PAD. To gain further insight
n the relationship between Ile164 and atherosclerosis, we
xtended our analysis to a previously published population
f 150 patients affected by PAD (13). This population
resented a high risk for CAD, and therefore, we assessed
he incidence of AMI or combined events such as coronary
rtery bypass graft, PCI, or AMI. Similar to what we found
n our original population, we observed that the presence of
he Ile164 allele was more frequent in PAD patients
ompared with the study control population (7.3% vs. 3%,
ngiographic Characteristics of B2AR Ile164 Patients
Table 2 Angiographic Characteristics of B2AR Ile164 Patients
Variable
Group 1
(n  290)
Group 2
(n  40) p Value
Coronary artery disease, %
LAD 60.6 53.8 NS
CX 69.3 35.9 NS
DX 33.1 59 0.002
Lesion type B2/C, % 75.5 100 0.048
More than 1 vessel treated, % 21.6 42.5 0.005
Multivessel disease, % 25.4 41 0.044
TIMI flow grade 3 after PCI, % 97 96.5 NS
X  left circumflex coronary artery; DX  right coronary artery; LAD  left anterior descending
oronary artery; TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1. 0.144), and no homozygous Ile164 individual wasound. Moreover the presence of the Ile164 polymorphism
as associated with a higher incidence of severe cardiovas-
ular clinical outcome assessed either by AMI (54.5% vs.
5.2%, p  0.035) or combined events (AMI, PCI, or
oronary artery bypass graft) (63.6% vs. 30.9%, p  0.027).
ndeed, in this population, the Ile164 allele increased the
isk of severe cardiovascular clinical outcome as confirmed
y Cox regression analysis after correction for multiple
ovariates (OR: 7.803, 95% CI: 1.358 to 5.730, p  0.005).
arotid ultrasound analysis. Carotid ultrasound analysis
as performed during hospitalization. Patients harboring
he Ile164 polymorphism presented a significantly increased
mount of atherosclerotic plaque in the carotid vascular
istrict (1.3  0.1 vs. 0.6  0.2, p  0.035). Accordingly,
MT was significantly higher in these patients (Fig. 2A).
nterestingly, plaque analysis performed by correct IBS
echnique suggests a different plaque composition between
roups with a higher presence of “soft tissue” in Ile164
atients (Fig. 2B). These data suggest a more aggressive
evelopment of atherosclerosis in presence of the Ile164
ene polymorphism.
n vitro data. We have previously demonstrated that the
le164 variant of the B2AR gene in endothelial cells loses
he ability to mediate cell specific responses to catechol-
mine (10,22). Here, to gain better insight on the role of
le164 on atherosclerosis, we explored the effect of this
olymorphism on VSMC proliferation in culture. In sub-
onfluent rat aorta VSMC, the ISO caused a significant
ncrease in cell number after 24 h (Fig. 3A). Consistent with
n effect on cell proliferation, beta-AR stimulation with
SO resulted in an increase in [3H]-thymidine incorpora-
ion (Fig. 3B), an index of DNA synthesis, and phosphor-
lation of Rb protein, indicative of progression in the cell
ycle (Figs. 3C and 3D). Moreover, we found that ISO
eads to significant ERK activation. To amplify the B2AR
ignal and better dissect the effect of the B2AR Ile164
olymorphism on biological responses of VSMC, we in-
Figure 1 Observed Event-Free Survival Curve at Follow-Up
Patients harboring the ThrIle164 allele of the beta2-adrenergic receptor gene
(group 2) had a higher incidence of major adverse cardiac events with reduced
event-free follow-up time as indicated by the Kaplan-Meier analysis.
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October 21, 2008:1381–8 Ile164 Polymorphism and CADected cells with either adenoviral (Ad) B2AR-164WT or
he Ad B2AR-Ile164. This maneuver guarantees that after
6 h from infection, the B2AR density increases 3-fold by
adioligand binding with both viruses (VSMC: 110  5
mol/mg; VSMC  Ad B2AR-164WT: 345  14 fmol/mg;
SMCAd B2AR-Ile164: 337 13 fmol/mg). Adenoviral-
ediated overexpression of the B2AR-WT but not the
2AR-Ile164 enhanced ERK/mitogen-activated protein
inase activation to ISO (Figs. 3E and 3F). Similarly,
verexpression of the B2AR-WT but not the Ile164-B2AR
esulted in increased cell proliferation and DNA synthesis as
easured by [3H]-thymidine incorporation, even in the
bsence of ISO. Agonist-mediated B2AR stimulation fur-
her enhanced these mitogenic responses (Figs. 3A and 3B).
ccordingly, data on phosphorylated Rb confirm these
esults (Figs. 3C and 3D). All together, these results
onfirm that the B2AR Ile164 is challenged to induce
atecholamine-mediated VSMCs’ proliferative responses.
iscussion
he main finding of this study is that the close relationship
etween the Ile164 polymorphism of the B2AR gene and a
iffuse and severe atherosclerosis has a significantly higher
isk of death and overall MACE compared with the
Figure 2 Carotid Ultrasound Analysis
Patients harboring the ThrIle164 allele showed a diffuse carotid atherosclerotic
disease with a significantly higher incidence of atherosclerotic plaque. (A) In
accordance with a more severe atherosclerotic carotid disease, intima-media
thickness (IMT) was significantly higher in ThrIle164 patients. (B) Plaque com-
position was analyzed with integrated backscatter (IBS) ultrasound technique.
Patients with Thr164Thr polymorphism presented lesions with a significantly
lower IBS value in the carotid artery as an index of different plaque composi-
tion between groups with a higher presence of “soft tissue” in ThrIle164
patients. Values are reported as mean  SD.ild-type B2AR. Moreover, the Ile164 gene polymorphism desults in a strong independent predictor of worse prognosis
t long-term follow-up. To identify the possible mecha-
ism, we investigated the nature of atherosclerotic plaque by
BS ultrasound and found peculiarities of the carotid
therosclerosis plaque in patients harboring Ile164 polymor-
hism. These differences can be explained by a different
ontent in VSMCs, which are less prone to proliferation in
le164 B2AR patients. Our corollary data support a role for
his polymorphism on the pathogenesis of a plaque that has a
ifferent composition due to a defect in VSMC proliferation.
arly and diffuse atherosclerosis in Ile164 subjects. We
ound an association between CAD onset age and the
resence of B2AR Ile164. Although there were no signifi-
ant differences in mean age between groups (60.10 vs. 60.8
ears in group 2, p  NS), when we compared the age at
nset of CAD, we found a significantly younger age in
roup 2 (56.7 vs. 59.5 years, p 0.04), suggesting an earlier
evelopment of CAD. Atherosclerosis is a diffuse process
hat starts early in childhood and progresses asymptomati-
ally through adult life affecting different vascular territories
25). Accordingly, we found a disease involving different
ascular districts. The presence of a severe CAD was
ngiographically confirmed by the observation of a higher
ncidence of type B2/C lesions, a larger occurrence of
ultivessel disease, and a significantly higher number of
evere lesions needing treatment by PCI. Interestingly, we
ound a significantly higher number of atherosclerotic
laque in patients harboring the Ile164 with a higher IMT
alue. Therefore, data on carotid and coronary arteries
isease suggest an association between the Ile164 polymor-
hism of the B2AR gene and the development of a severe
nd diffuse atherosclerosis.
oor outcome in B2AR Ile164 subjects. In our study, we
ound a strong association between Ile164 and prognosis.
ndeed, overall MACE were significantly higher in patients
ith the Ile164 variant compared with the WT receptor.
espite the wide use of coronary stenting and the optimal
esult of PCI, with a similar rate of TIMI antegrade flow
rade 3 after procedure, group 2 showed a significant higher
revalence of adverse clinical events with a higher incidence
f new PCI, new AMI, heart failure, and cardiac death. Cox
egression analysis identified the presence of the Ile164
olymorphism as a strong independent risk factor for
dverse clinical outcomes associated with a higher risk for
ardiac death. The association between Ile164 and athero-
clerosis was confirmed in a replication study. In an inde-
endent population of patients affected by PAD, and
herefore at risk for CAD, the Ile164 polymorphism prev-
lence, although not significant, was higher than in the
resent control population and almost all previously pub-
ished control populations (1,6). Moreover, those harboring
he B2AR Ile164 polymorphism showed a 3.6 increased
isk to develop AMI and a 3.9 increased risk to develop a
ajor cardiovascular event. These data confirm the prog-
ostic role of the B2AR’s 164 position in cardiovascular
isease.
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Ile164 Polymorphism and CAD October 21, 2008:1381–8otential mechanism. The proliferation of VSMCs is a
ey event in the formation of atherosclerotic lesions and
he development of restenosis following angioplasty (26 –
8). Studies in coronary atherectomy specimens showed
hat in patients with unstable plaque, the numbers of
nflammatory cells increased, whereas, the number of
SMCs decreased reciprocally to the severity of the
linical presentation of CAD (29). In this study, we
ound that VSMC proliferation is impaired in patients
Figure 3 In Vitro Effects of B2AR Stimulation on VSMC Biology
Panel A shows the proliferative response in subconfluent vascular smooth muscle
cles) but not the Ad B2AR-Ile164 mutation (in which isoleucine is located at posit
[CTR]; analysis of variance [ANOVA], with Bonferroni post-hoc test). Isoproterenol (
Panel B shows deoxyribonucleic acid (DNA) synthesis by [3H]-thymidine incorporati
same effect was obtained in Ad B2AR-WT but not in Ad B2AR-Ile164. The maximal
#p  0.05 vs. control; ANOVA, with Bonferroni post-hoc test; n  3 in duplicate).
(Rb) phosphorylation. This protein regulates cell-cycle progression through the rest
mol/l), caused Rb phosphorylation (P-Rb). Equal amount of proteins were confirme
tion caused Rb activation, and Ad B2AR-WT treatment induced Rb activation. The I
densitometry units (ADU); *p  0.05 versus control; #p  0.05 versus the ThrIle1
Bonferroni post-hoc test (n  3 in duplicate). Panels E and F show extracellular si
blot of activated phosphorylated ERK (pERK) after ISO treatment. Equal amount of
in the inset. Densitometric analysis (bar graph) shows that B2AR stimulation caus
ISO (107mol/l) response was enhanced (*p  0.05 vs. no ISO; #p  0.05 vs. barrying the Ile164 polymorphism as shown by reduced eell proliferation, [3H]-thymidine incorporation and Rb
hosphorylation. We can speculate that a dysfunctional
2AR leads to a reduced cellularity in atherosclerotic
laques due to a reduction in VSMC proliferation leading
o development of plaques more prone to instability and
upture. Accordingly, patients with Ile164 polymorphism
howed a 4.5 increased risk of developing a new AMI.
ur hypothesis is further supported by the IBS analysis
f carotid arteries plaques. Measurement of IBS to
(VSMCs). Adenoviral beta2-adrenergic receptor–wild type (Ad B2AR-WT) (open cir-
4) (open triangles) produced a proliferative response (*p  0.05 vs. control
07 mol/l) caused an increase of cell numbers over time (solid symbols).
e activation of B2AR by ISO (107 mol/l) caused increased DNA synthesis. The
nse was observed in ISO-stimulated Ad B2AR-WT cells (*p  0.05 vs. no ISO;
C and D show the progression in cell cycle assessed by retinoblastoma protein
point within the G1 phase. By Western blot at 24 h of stimulation, ISO (107
lotting for actin. Densitometric analysis (bar graph) shows that B2AR stimula-
7 mol/l) response was enhanced. These amounts were measured in arbitrary
lymorphism (threonine is replaced by isoleucine at position 164) ANOVA, with
lated kinase/mitogen-activated protein kinase (ERK/MAPK) activation. Western
ns were confirmed via blotting for total ERK. Representative blots are presented
K/MAPK activation, and that Ad B2AR-WT treatment induced ERK activation. The
NOVA, with Bonferroni post-hoc test; n  3 in duplicate).cells
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October 21, 2008:1381–8 Ile164 Polymorphism and CADechnique to distinguish atheromatous (fibrofatty lesion
ith a lower IBS) tissue from fibrous tissue (fibrocalcific
esion with a higher IBS) (30), and carotid IMT by
ltrasound was recently reported as a good surrogate
arker of coronary atherosclerosis (31). We found in vivo
significantly higher incidence of lower-IBS lesions in
he carotid arteries of patients with Ile164 polymor-
hism, which is consistent with the presence of athero-
clerotic plaque with a lower VSMC component in
atients carrying this gene polymorphism. Moreover,
hese patients presented a significantly higher incidence
f a new PCI. Because VSMCs are the sole producers of
he tensile components of the extracellular matrix (nota-
ly of collagen type I), a decrease in their numbers would
ead to diminished production of the plaque-stabilizing
olecules and, therefore, to reduced plaque stability.
hus, we can speculate that alteration in vessel biology,
amely VSMC proliferation and/or endothelial cell turn
ver, can be responsible for these phenomena leading to
very poor clinical outcome for patients.
tudy limitations. Limitations of the study include those
nherent to any prospective but observational study. Because
his is an association study, we cannot rule out the presence
f a possible linkage disequilibrium with other neighboring
enes that might explain the significant association with
therosclerotic phenotype or adverse prognosis. The study
as conducted in patients with severe CAD undergoing
CI and the replication study was performed in patients
ith PAD; therefore, our findings need to be confirmed in
urther larger patient populations. Nevertheless, a recent
tudy (32) underlines the need for selection of patients in
ssociation studies in order to identify the populations in
hich single gene polymorphisms may be more determinant
n complex phenotypes such as CAD. Finally, all patients
eceived bare metal stents during PCI; therefore, we cannot
xclude a reduced incidence of new PCI at long-term
ollow-up using drug eluting stents. However, the efficacy
nd safety of the use of drug eluting stents on long-term
utcome remains to be established and, in the recent
RACI III (Randomized Trial of Percutaneous Translu-
inal Coronary Angioplasty Versus Coronary Artery By-
ass Surgery in Multivessel Disease) study (33), the initial
dvantage over bare metal stents appeared to decrease with
ime.
onclusions and Clinical Implications
ur study suggests that the B2AR-Ile164 mutant is asso-
iated with an earlier and more aggressive CAD, and it
dversely affects prognosis in patients with severe CAD
ndergoing PCI. These findings confirm the pivotal role of
2AR function in the cardiovascular system and add new
vidence to existing data on the linkage between B2AR
unction and outcome in heart disease.eprint requests and correspondence: Prof. Federico Piscione,
epartment of Cardiology, Federico II University, Via S. Pansini,
, 80131 Naples, Italy. E-mail: piscione@unina.it.
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